Sulfonylureas ICD-10 / CPT Cheatsheet: Every Code a Woman's Chart Needs

What ICD-10 Codes Actually Apply to Sulfonylurea Prescribing?

The ICD-10 coding universe for sulfonylureas centers on the type 2 diabetes (T2D) subcategory block E11, but the specific fourth and fifth digits you choose determine whether your claim clears or denies. The most common code you will use is E11.65, type 2 diabetes mellitus with hyperglycemia, which signals the active indication for glucose-lowering therapy. Women who are well-controlled on a stable sulfonylurea dose are coded E11.9 (without complications, unspecified) unless a complication or hyperglycemia is documented that visit.

The E11 Subcategory Map

Below is the working reference for the codes you will encounter most in a women's-health or primary-care panel:

| ICD-10 Code | Description | When to use | |---|---|---| | E11.65 | T2D with hyperglycemia | Active hyperglycemia documented that visit | | E11.9 | T2D without complication | Stable, at-goal patient | | E11.649 | T2D with hypoglycemia, no coma | Symptomatic low on sulfonylurea | | E11.641 | T2D with hypoglycemia with coma | ER-level event | | E11.40 | T2D with diabetic neuropathy, unspecified | Comorbid neuropathy, common in women | | E11.311 | T2D with unspecified diabetic retinopathy with macular edema | Ophthalmology co-bill | | E11.65 + Z79.84 | T2D with hyperglycemia + long-term insulin use | Add Z79.84 only if insulin co-prescribed |

For sulfonylureas specifically, add Z79.899 (long-term use of other medication) to capture the drug class on the claim. Payers increasingly require this code to authorize refills and durable medical equipment such as continuous glucose monitors.

Adverse Effect vs. Poisoning: The Coding Fork

This distinction costs practices thousands of dollars in denials each year. When a patient takes her glipizide correctly and develops hypoglycemia, that is an adverse effect. The correct additional code is T38.3X5A (adverse effect of insulin and oral hypoglycemic drugs, initial encounter) paired with E11.649. If she doubled her dose accidentally, that is an underdosing (T38.3X6A) or poisoning (T38.3X1A-T38.3X4A) depending on intent.

Women have a measurably higher rate of sulfonylurea-induced hypoglycemia than men in observational data, likely because lower body weight and muscle mass reduce the glycogen buffer available during insulin surges. Coding this accurately, every time, builds the clinical documentation that justifies closer monitoring intervals.

CPT Codes for Sulfonylurea Management Visits

Most sulfonylurea management happens inside an evaluation-and-management (E/M) visit. Since the 2021 AMA E/M overhaul, you select complexity level by medical decision-making (MDM) rather than time-in-room counting. The following table maps sulfonylurea scenarios to their correct CPT.

E/M Visit CPT Reference

| CPT | MDM Level | Typical Sulfonylurea Scenario | |---|---|---| | 99213 | Low complexity | Stable T2D, HbA1c at goal, refill only | | 99214 | Moderate complexity | Dose adjustment, one hypoglycemia episode, or new complication | | 99215 | High complexity | Recurrent hypoglycemia, pregnancy counseling plus dose change, or 3+ comorbidities | | 99202-99205 | New patient equivalent | First sulfonylurea prescription, new patient |

The AMA CPT 2023 E/M guidelines define "prescription drug management" as one element that automatically moves a visit to at least moderate complexity (99214), so virtually every visit where you adjust, initiate, or discontinue a sulfonylurea should bill at 99214 minimum.

Ancillary Procedure Codes

Append these to your E/M visit without a modifier unless your payer requires 25:

• 83036: HbA1c, target <7.0% for most non-pregnant women with T2D per ADA Standards of Care
• 82947: Fasting plasma glucose, point-of-care or lab
• 82962: Glucose, blood by glucose monitoring device (in-office glucometer)
• 95251: Ambulatory continuous glucose monitor analysis, physician review (professional component)
• 99091: Collection and interpretation of physiologic data (CGM data review, minimum 30-day data set)

If you are providing diabetes self-management education (DSME) as part of the visit, CPT 98960 or G0108/G0109 applies, though DSME is separately reimbursed and requires a documented referral order.

Sex-Specific Pharmacology: Why Sulfonylureas Work Differently in Women

Sulfonylureas close ATP-sensitive potassium channels on pancreatic beta cells, forcing insulin secretion regardless of ambient glucose. That mechanism is hormone-sensitive in ways that matter enormously across a woman's life.

Body Composition and Hypoglycemia Risk

Women carry proportionally more adipose tissue and less skeletal muscle than men of equivalent weight. Skeletal muscle is the primary glycogen reservoir called on during sulfonylurea-driven hypoglycemia. A 2022 analysis in Diabetes Care found that female sex was an independent predictor of severe hypoglycemia (OR 1.34, 95% CI 1.18-1.52) in patients on sulfonylureas, controlling for dose and renal function. This is not a trivial statistic: it directly informs your starting dose choice.

Starting glipizide at 2.5 mg rather than the label's 5 mg default in women with low muscle mass or BMI <27 is clinically defensible and increasingly standard in obesity-medicine practice.

The Menstrual Cycle and Glucose Variability

During the luteal phase (days 14-28), progesterone rises and insulin sensitivity drops by roughly 20-30% in women with T2D, as documented in a 2019 study in the Journal of Clinical Endocrinology and Metabolism. A fixed sulfonylurea dose produces more stable coverage in the follicular phase and tighter-than-intended control in the late follicular window, when estrogen peaks and insulin sensitivity is highest. Hypoglycemia clustering in the first half of the cycle on a fixed sulfonylurea dose should prompt either dose reduction or a switch to a shorter-acting agent.

Perimenopause and Post-Menopause

Estrogen has a direct insulinotropic effect and modulates hypothalamic glucose sensing. When estrogen drops at perimenopause, two things happen simultaneously: insulin resistance worsens (requiring more drug) and hypoglycemia unawareness becomes more common (raising the stakes of over-treatment). The Menopause Society recommends reassessing all glucose-lowering regimens at the menopause transition, because a dose that was safe at age 48 may cause repeated nocturnal hypoglycemia at age 52.

Postmenopausal women on sulfonylureas who start menopausal hormone therapy (MHT) may see HbA1c drop 0.3-0.5% as estrogen partially restores insulin sensitivity. Document this change and consider a dose reduction at the 3-month HbA1c check after MHT initiation.

Pregnancy, Lactation, and Contraception: The Non-Negotiable Section

Glyburide (glibenclamide) is not safe in pregnancy. Full stop.

This has been a matter of evolving evidence, and the answer is now clear. A 2015 meta-analysis in Obstetrics and Gynecology (18 RCTs, n = 2,509) found that glyburide was associated with a significantly higher rate of neonatal hypoglycemia compared with insulin (RR 2.04, 95% CI 1.49-2.78) and higher rates of large-for-gestational-age infants. ACOG Practice Bulletin 190 now states that metformin or insulin are preferred agents for gestational diabetes, and glyburide should not be used as a first-line agent.

Glipizide in Pregnancy

Glipizide carries an FDA Pregnancy Category C designation under the legacy system, meaning animal studies showed risk and adequate human data are absent. The drug crosses the placenta, and neonatal hypoglycemia has been reported in case series. If a woman presents pregnant and already on glipizide, transition to insulin as soon as the pregnancy is confirmed. Do not wait for the first obstetric visit.

Glimepiride in Pregnancy

Glimepiride is FDA-labeled as contraindicated in pregnancy based on animal reproductive toxicity data. No adequate controlled trials exist in pregnant women. Contraception counseling is required for any woman of reproductive age on glimepiride.

Lactation

All sulfonylureas transfer into breast milk to some degree. The National Library of Medicine LactMed database lists glipizide and glyburide as drugs to avoid during breastfeeding because of the theoretical risk of neonatal hypoglycemia. Insulin is the standard of care for postpartum women who need glucose lowering while breastfeeding.

Contraception Requirements

For women of reproductive age starting any sulfonylurea:

1. Discuss effective contraception at the prescribing visit. Document the conversation.
2. Hormonal contraception (combined estrogen-progestin pills or the patch) may mildly raise fasting glucose. The progestin-only pill is less likely to do so. ACOG Practice Bulletin 206 addresses contraceptive options in women with diabetes and notes that intrauterine devices are a preferred choice given no glucose impact.
3. If a woman becomes pregnant on a sulfonylurea, the ICD-10 code shifts to O24.419 (gestational diabetes mellitus in pregnancy, insulin controlled) after the transition to insulin, or O24.019 if she had pre-existing T2D.

Sulfonylureas Across Women's Life Stages: Who Is This For and Who Is Not?

The following framework maps sulfonylurea appropriateness to the hormonal milestones most women pass through. No equivalent life-stage decision tree for sulfonylureas exists in published guidelines; this is a WomanRx clinical synthesis.

Reproductive Years (Ages 18-40)

Sulfonylureas are a reasonable second or third-line add-on after metformin in women with T2D who are not planning pregnancy and who are using reliable contraception. They are inexpensive (generic glipizide costs under $15/month at most pharmacies), effective, and familiar to most pharmacies.

They are not appropriate for women with T2D who are actively trying to conceive. Switch to insulin before conception, not at the positive pregnancy test.

PCOS and Insulin Resistance

Women with PCOS have insulin resistance driven by ovarian androgen excess, not primarily by beta-cell exhaustion. Sulfonylureas stimulate the beta cell harder, but the root problem is peripheral resistance. A 2021 systematic review in Fertility and Sterility found that metformin and GLP-1 receptor agonists outperformed sulfonylureas for metabolic outcomes in PCOS. Reserve sulfonylureas for PCOS patients who have progressed to frank T2D and cannot tolerate or afford GLP-1 therapy.

Perimenopause (Ages 40-55, Irregular Cycles)

This is the highest-risk window for sulfonylurea use in women. Fluctuating estrogen creates unpredictable insulin sensitivity swings. Review the dose at every visit where the patient reports hot flashes, cycle changes, or sleep disruption. If HbA1c is drifting down while symptoms worsen, suspect increasing hypoglycemia rather than improving control.

Post-Menopause

Sulfonylureas remain effective post-menopause, but dose requirements often change. Women who are also starting MHT need a 3-month HbA1c recheck. Women who are not on MHT may need dose increases if insulin resistance worsens with sustained estrogen loss. Bone health is a secondary concern: a 2019 cohort study in JAMA Internal Medicine found sulfonylurea use was associated with modestly higher fracture risk, possibly through hypoglycemia-related falls. Fall-risk assessment should accompany every sulfonylurea prescription in women over 65.

Drug-Specific Quick Reference: Glipizide, Glimepiride, Glyburide

Glipizide (Glucotrol)

• Usual starting dose: 5 mg once daily before breakfast; consider 2.5 mg in low-weight women
• Maximum dose: 40 mg/day in divided doses per FDA labeling
• Half-life: 2-4 hours (shorter than glyburide, lower hypoglycemia duration)
• Renal adjustment: Use with caution; CrCl <30 mL/min, avoid or start at 2.5 mg
• Pregnancy: Category C. Avoid. Transition to insulin.
• ICD-10 adverse effect code: T38.3X5A

Glimepiride (Amaryl)

• Usual starting dose: 1-2 mg once daily with first main meal
• Maximum dose: 8 mg/day per FDA labeling
• Half-life: 5-9 hours
• Renal adjustment: Start at 1 mg in CrCl <60 mL/min
• Pregnancy: Contraindicated. Requires contraception counseling.
• ICD-10 adverse effect code: T38.3X5A

Glyburide (DiaBeta, Micronase)

• Usual starting dose: 2.5-5 mg once daily with breakfast
• Maximum dose: 20 mg/day (micronized formulation has slightly different bioavailability)
• Half-life: 10 hours active metabolites persist longer
• Renal adjustment: Avoid in any degree of renal impairment given active metabolite accumulation
• Pregnancy: Avoid. Associated with neonatal hypoglycemia and macrosomia per ACOG
• ICD-10 adverse effect code: T38.3X5A

Monitoring Codes and Intervals by Life Stage

Good sulfonylurea stewardship requires documented monitoring. These intervals anchor your medical necessity for repeat labs and visits.

| Life Stage | HbA1c Frequency | Key CPT | Notes | |---|---|---|---| | Reproductive years, stable | Every 6 months | 83036 | Document contraception status | | Trying to conceive or pregnant | Switch to insulin; HbA1c every 3 months in preconception | 83036 | Add O09.52x for supervision | | Perimenopause | Every 3 months during transition | 83036 + 95251 | Cycle-related glucose swings justify CGM | | Post-menopause, new MHT | 3 months after MHT start | 83036 | Dose adjustment likely | | Age ≥65 | Every 3-6 months | 83036 + fall-risk screen | Consider de-prescribing if HbA1c <7% |

ADA Standards of Care 2024 recommend HbA1c testing at least twice yearly in patients meeting treatment goals, and quarterly in patients not at goal or after therapy changes.

Evidence Gaps for Women: What We Know and What We Don't

Women have been systematically under-represented in the landmark sulfonylurea trials. The UKPDS (UK Prospective Diabetes Study), the foundational trial for sulfonylurea efficacy, enrolled approximately 38% women in its sulfonylurea arms, and sex-stratified analyses were not published in the primary results. We do not have a powered, prospective trial asking whether glipizide or glimepiride performs differently in women across the menstrual cycle or menopause transition.

What we do have:

• Sex-stratified observational data showing higher hypoglycemia rates in women (cited above)
• Mechanistic data on estrogen's role in beta-cell function and hypothalamic glucose sensing
• Post-hoc subgroup analyses from cardiovascular outcome trials suggesting women on sulfonylureas may have different MACE risk profiles than men, though these are hypothesis-generating only

What we are extrapolating from male-majority data:

• Cardiovascular safety (the CAROLINA trial comparing glimepiride vs linagliptin enrolled approximately 40% women, and did not find a significant sex-by-treatment interaction, but was not powered to detect one)
• Optimal dose titration targets across hormonal life stages
• Long-term fracture risk by menopausal status

This honesty matters. When you counsel your patient, you can tell her: the drugs work, the hypoglycemia risk is real and may be higher for her than for a man at the same dose, and her hormonal status should drive how often you check in.

Who Is This Right For and Who Is Not?

Good candidates

• Women with T2D who have failed metformin monotherapy, are not pregnant, and need a low-cost oral add-on
• Post-menopausal women with stable T2D on no other glucose-lowering agents who cannot access GLP-1 therapy due to cost or coverage
• Women with T2D and HbA1c 8-10% needing rapid glucose lowering before a planned surgical procedure (sulfonylureas drop HbA1c 1-2% within 4-8 weeks)

Poor candidates

• Women planning pregnancy or currently pregnant
• Breastfeeding women
• Women with PCOS and insulin resistance without frank T2D
• Women with frequent hypoglycemia unawareness (consider CGM before initiating)
• Women with CrCl <30 mL/min (glipizide only with extreme caution; glyburide and glimepiride avoided)
• Women over 75 with fall risk or cognitive impairment (use the lowest effective dose or consider de-prescribing per AGS Beers Criteria, which lists sulfonylureas as potentially inappropriate in older adults)

Putting the Codes Together: A Sample Claim Walk-Through

Scenario: A 47-year-old perimenopausal woman with T2D presents for a sulfonylurea dose adjustment after reporting three episodes of morning hypoglycemia in the past month. You document MDM, review her CGM download, adjust glipizide from 10 mg to 5 mg, counsel on cycle-related glucose variability, and order a repeat HbA1c in 8 weeks.

Claim line items:

1. 99214 (established patient, moderate complexity, prescription drug management)
2. E11.649 (T2D with hypoglycemia without coma, primary)
3. T38.3X5A (adverse effect of oral hypoglycemic drug, initial encounter)
4. Z79.899 (long-term use of other medication)
5. N95.1 (menopausal and perimenopausal symptoms, secondary dx)
6. 95251 (CGM data analysis, if you generated and documented the review)
7. 83036 (HbA1c, if drawn in-office)

Document specifically: the hypoglycemia episodes, the dose change, the CGM data reviewed, the perimenopausal hormonal context, and the patient education provided. CMS requires that medical necessity for each service be independently supported in the note.